How human challenge models can accelerate vaccine development

Human challenge models can provide early, controlled, and decision-relevant evidence for vaccine and therapeutics development. Used appropriately, they can help development teams understand whether a candidate vaccine or a drug is likely to generate meaningful protection, clarify dose and regimen choices, and support better decisions before larger and more expensive field efficacy studies.

Why human challenge models matter

Vaccine and drug development often depends on evidence generated across different settings: preclinical systems, immunogenicity studies, natural exposure, field efficacy trials, and post-licensure effectiveness data. Each source of evidence has strengths, but also important limitations.

Human challenge models can fill a specific gap in this evidence pathway. By exposing carefully selected, healthy adult volunteers to a well-characterised pathogen under controlled clinical conditions, challenge studies can generate early efficacy, immune response, and disease-course data in a relatively compact setting.

This does not replace large field trials. Instead, it can help development teams make sharper decisions before moving into larger, slower, and more expensive studies. For vaccines against respiratory viruses, where attack rates, seasonality, strain selection, and endpoint definitions can all complicate field efficacy assessment, this controlled evidence can be particularly valuable.

Where challenge studies can add value

Human challenge studies are most useful when they are designed around a clear development question. They can help generate evidence at points where conventional clinical development may be too slow, too variable, or too dependent on unpredictable epidemiology.

For vaccine and drugs programs, a challenge model can support several strategic decisions: whether a candidate has a credible protective signal, whether immune responses translate into reduced infection or disease, whether a dose or schedule is worth advancing, and how endpoints should be defined for later studies.

They can also help compare candidates or formulations under controlled conditions. This can be especially useful when multiple development options are available, but resources, time, or clinical trial opportunities are limited.

The value is not only scientific. A well-designed challenge study can also create decision-ready evidence for internal governance, partner discussions, investor communication, and regulatory planning.

What challenge models cannot answer

Human challenge models are powerful tools, but they have clear boundaries. They are usually conducted in carefully selected adult volunteers, under controlled conditions, with a defined challenge strain and protocol-driven clinical follow-up. This means they cannot fully reproduce the complexity of real-world exposure, population heterogeneity, comorbidities, age-related risk, or long-term effectiveness.

A challenge study should therefore not be positioned as a universal substitute for field efficacy trials or broader clinical evidence. Its value depends on asking the right question and interpreting the result in the right development context.

For example, a positive challenge result can provide confidence that a candidate has biological and clinical activity under controlled conditions. However, it does not automatically define real-world effectiveness across seasons, populations, geographies, or evolving viral strains.

This is why challenge models should be integrated into a broader evidence strategy rather than treated as a stand-alone answer.

Strategic questions before using a challenge model

Before using a human challenge model, development teams should be clear about the decision the study is intended to support. A challenge study is most valuable when it is linked to a specific question that can change the development path.

Key questions include: What decision will be made if the study is positive, negative, or inconclusive? Which endpoint is most relevant: infection, symptoms, viral load, disease severity, immune response, or a composite measure? Is the selected challenge strain appropriate for the vaccine’s intended positioning? How will the results be interpreted alongside immunogenicity, safety, field epidemiology, and regulatory expectations?

The operational design also matters. Volunteer selection, challenge dose, timing of vaccination, sampling schedule, endpoint definitions, and statistical assumptions all influence whether the study will generate interpretable evidence.

A challenge model should therefore be treated as a strategic development tool, not only as a clinical experiment. Its design should connect the scientific question, the clinical endpoint, and the downstream decision.

How independent expertise can help?

Independent scientific input can help teams decide whether a human challenge model is appropriate, how it should be positioned, and what type of evidence it can realistically generate.

This can include reviewing the scientific rationale, assessing whether the challenge model is aligned with the product profile, identifying key design risks, and clarifying how the results should be communicated to internal teams, investors, partners, CROs, or regulators.

For biotech and life sciences organizations, this external perspective can be particularly valuable when development decisions need to be made quickly, when internal resources are limited, or when a program must be translated into a clear strategic narrative.

The goal is not simply to run a challenge study. The goal is to generate evidence that is credible, interpretable, and useful for decision-making.

Conclusion

Human challenge models can play an important role in vaccine development when they are used for the right question, at the right point in the development pathway, and with a clear understanding of their strengths and limitations.

They can help teams generate early controlled evidence, refine development strategy, compare candidates, and prepare for larger clinical studies. Their greatest value is not only in the data they produce, but in the decisions that those data enable.

For biotech, pharma, CRO, and life sciences teams developing vaccines or antivirals against respiratory viruses, challenge models can provide a focused and decision-relevant way to reduce uncertainty and sharpen clinical strategy.

Noulin BioConsulting provides independent scientific and strategic support for organizations considering, designing, or positioning human challenge models within vaccine and antiviral development programs.

To discuss a vaccine/Antiviral development or human challenge model strategy project, contact Noulin BioConsulting.